Tag archive for ‘Immuno oncology drug’
By pharmanewsdaily On Tuesday, September 11th, 2018
0 Comments

Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors

Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor More...

By pharmanewsdaily On Wednesday, July 18th, 2018
0 Comments

Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab

Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination of Voyager-V1 and Bavencio (avelumab), respectively, for More...

By pharmanewsdaily On Sunday, April 16th, 2017
0 Comments

APAC Biotech’s Immuno-oncology drug Apceden gets approved in India

The Indian FDA (CDSCO – Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous Immuno-oncology drug for prostate, More...